Case Report: Genotype-informed management after clinically necessary cytoreduction for giant recurrent gastric gastrointestinal stromal tumor with prior rupture and KIT exon 17 N822Y mutation
- 1Department of Abdominal Surgery, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University
- 2Department of Radiology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University
- 3Department of Pathology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University
Abstract
Advanced recurrent gastrointestinal stromal tumor (GIST) after prolonged tyrosine kinase inhibitor (TKI) exposure requires integration of surgical oncology, molecular reassessment, and continuous systemic therapy. We report a 72-year-old man with a 21-year history of gastric GIST who underwent initial resection in 2005, resection of recurrent disease in 2009, and long-term imatinib therapy. After years of apparent disease stability, he independently reduced imatinib and had a prolonged surveillance gap before recurrence was detected in 2024. Following tumor rupture and short-interval progression on sunitinib and regorafenib, he received ripretinib. In January 2026, clinically necessary maximal cytoreductive surgery was performed for bulky recurrent peritoneal disease with bleeding, anemia, abdominal-wall involvement, high risk of re-rupture, and invasion or close involvement of the right colon. Pathology confirmed recurrent high-risk spindle-cell GIST. Postoperative next-generation sequencing identified a founding KIT exon 11 deletion and a secondary KIT exon 17 p.Asn822Tyr activation-loop mutation; ripretinib was resumed after recovery of oral intake. Three-month CT showed recurrent peritoneal tumors, while a right hepatic subcapsular low-enhancement nodule was favored to represent post-ablation change. This case illustrates that surgery in resistant recurrent GIST may be necessary for local complication control and tissue acquisition, but even after maximal macroscopic cytoreduction, durable management depends on continuous genotype-informed systemic therapy and close surveillance.
Related
- Tranexamic acid use and progression to clinically important bleeding in critically ill patients with non-clinically important non-variceal upper gastrointestinal bleeding: a retrospective cohort study
- Thrombophilia Testing After VTE and in Related Clinical Contexts: Is It Necessary, and Does It Change Management? Appraisal of Evidence, Guidelines, and Clinical Yield
- A distinct gastrointestinal symptom profile characterizes clinically relevant fatigue in systemic sclerosis
- Serial Upper Gastrointestinal Endoscopy Guided Clinical Management in Extensive Allopurinol-Induced Toxic Epidermal Necrolysis
- Endoscopic self-expandable metal stent placement before conversion therapy for advanced and recurrent gastrointestinal malignancies: A single-center retrospective study.
BibTeX
@article{rui2026case,
title = {{Case Report: Genotype-informed management after clinically necessary cytoreduction for giant recurrent gastric gastrointestinal stromal tumor with prior rupture and KIT exon 17 N822Y mutation}},
author = {Jianrui Rui and Chaoqiang Cai and Yongyuan Chen and Tianbao Xu and Zhen Wang and Guanxiang Zhuo and Linhe Gan and Liting Xue and Xueying Zeng and Min Zhou and Weiji Ding},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1908617},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1908617/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Genotype-informed management after clinically necessary cytoreduction for giant recurrent gastric gastrointestinal stromal tumor with prior rupture and KIT exon 17 N822Y mutation
AU - Jianrui Rui
AU - Chaoqiang Cai
AU - Yongyuan Chen
AU - Tianbao Xu
AU - Zhen Wang
AU - Guanxiang Zhuo
AU - Linhe Gan
AU - Liting Xue
AU - Xueying Zeng
AU - Min Zhou
AU - Weiji Ding
PY - 2026
DA - 2026/10/08
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1908617
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1908617/full
AB - Advanced recurrent gastrointestinal stromal tumor (GIST) after prolonged tyrosine kinase inhibitor (TKI) exposure requires integration of surgical oncology, molecular reassessment, and continuous systemic therapy. We report a 72-year-old man with a 21-year history of gastric GIST who underwent initial resection in 2005, resection of recurrent disease in 2009, and long-term imatinib therapy. After years of apparent disease stability, he independently reduced imatinib and had a prolonged surveillance gap before recurrence was detected in 2024. Following tumor rupture and short-interval progression on sunitinib and regorafenib, he received ripretinib. In January 2026, clinically necessary maximal cytoreductive surgery was performed for bulky recurrent peritoneal disease with bleeding, anemia, abdominal-wall involvement, high risk of re-rupture, and invasion or close involvement of the right colon. Pathology confirmed recurrent high-risk spindle-cell GIST. Postoperative next-generation sequencing identified a founding KIT exon 11 deletion and a secondary KIT exon 17 p.Asn822Tyr activation-loop mutation; ripretinib was resumed after recovery of oral intake. Three-month CT showed recurrent peritoneal tumors, while a right hepatic subcapsular low-enhancement nodule was favored to represent post-ablation change. This case illustrates that surgery in resistant recurrent GIST may be necessary for local complication control and tissue acquisition, but even after maximal macroscopic cytoreduction, durable management depends on continuous genotype-informed systemic therapy and close surveillance.
SN - 2234-943X
ER -